{"id":120,"date":"2010-07-15T10:45:54","date_gmt":"2010-07-15T14:45:54","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=120"},"modified":"2010-07-15T10:45:54","modified_gmt":"2010-07-15T14:45:54","slug":"biotech-company-wins-nih-biodefense-grants","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=120","title":{"rendered":"Biotech Company Wins NIH Biodefense Grants"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/Mosquito_GermanMeyer_200.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-122\" title=\"Mosquito_GermanMeyer_200\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/Mosquito_GermanMeyer_200.jpg\" alt=\"Mosquito (Germ\u00e1n Meyer)\" width=\"200\" height=\"199\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/Mosquito_GermanMeyer_200.jpg 200w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/Mosquito_GermanMeyer_200-150x149.jpg 150w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a>MacroGenics Inc, a biotechnology company in Rockville, Maryland, today announced that the National Institutes of Health (NIH) has <a href=\"http:\/\/www.macrogenics.com\/press_releases-282.html\">awarded the company<\/a> three new grants representing total funding of $9.8 million. MacroGenics develops therapeutics to treat autoimmune disorders, cancer and infectious diseases.<\/p>\n<p>The company says the NIH grants will advance its Dual-Affinity Re-Targeting (DART) platform, as well as its portfolio of infectious disease product candidates.  Two of the grants are funded by NIH&#8217;s Partnerships for Biodefense Viral Pathogens, and cover research and development to create an antibody-based therapy for Chikungunya Virus and a DART-based pan-Dengue Virus immunotherapeutic for prevention and treatment of Dengue Virus. Both viruses are insect-borne and transmitted to humans by mosquitoes.<\/p>\n<p>A third grant will fund preclinical investigational new drug enabling activities on MacroGenics&#8217; Inflammation DART.  This DART specifically targets B lymphocytes with the potential to treat a broad range of autoimmune diseases including lupus, rheumatoid arthritis, and multiple sclerosis.<\/p>\n<p>Macrogenics says it has developed more than 60 different DART molecules and completing multiple <em>in vitro<\/em> and <em>in vivo<\/em> proof-of-concept studies with several prototypes.<\/p>\n<p>Photo: <a href=\"http:\/\/www.flickr.com\/photos\/kainet\/149523256\/\">Germ\u00e1n Meyer\/Flickr<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MacroGenics Inc, a biotechnology company in Rockville, Maryland, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million. MacroGenics develops therapeutics to treat autoimmune disorders, cancer and infectious diseases. The company says the NIH grants will advance its Dual-Affinity Re-Targeting (DART) platform, as [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,15],"tags":[38,39],"class_list":["post-120","post","type-post","status-publish","format-standard","hentry","category-finance","category-products","tag-grant","tag-nih"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=120"}],"version-history":[{"count":3,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/120\/revisions"}],"predecessor-version":[{"id":124,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/120\/revisions\/124"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}